Table 2 Drug-drug interactions and predicted plasma levels of antiarrhythmics and targeted cancer therapies
From: Management of atrial fibrillation in patients taking targeted cancer therapies
| Â | Â | Anti-arrhythmics | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Vaughan Williams Class | 1a | 1b | 1c | 2 | 3 | 4 | Misc. | |||||||||||||||
| Â | Â | Quin-idine | Diso-pyra-mide | Procai-namide | Lido-caine | Mexil-etine | Flec-ainide | Propa-fenone | Meto-prolol | Aten-olol | Carve-dilol | Labe-talol | Propr-anolol | Nad-olol | Pind-olol | Sotalol | Dofet-ilide | Ibut-ilide | Amio-darone | Drone-darone | Diltia-zem | Verap-amil | Digo-xin |
Tyrosine Kinase Inhibitors | Afatinib | TA D | Â | Â | Â | Â | Â | Â | Â | Â | TA D | Â | T D | A | Â | Â | Â | Â | TA D | T D | B | TA D | B |
Axitinib | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | T* | T* | T* | Â | |
Bosutinib | T | Q | Q | Â | Â | Q | Q | Â | Â | T | Â | T | A | Â | Q | Q | Q | T | T | T | T | A | |
Cabozantinib | A | Â | Â | Â | Â | Â | Â | Â | Â | A | Â | Â | A | Â | Â | Â | Â | TA | T* | T* | T* | A | |
Ceritinib | Q | Q | Q | T | Â | Q | B/Q | B | B | B | B | B | B | B | B/Q | Q | Q | B/Q | A/B/Q* | B* | B* | B | |
Crizotinib | Q | Q | Q | A | Â | Q | A/Q | B | B | TA/B | B | TA/B | A/B | B | Q | Q | Q | Q | Q | TA/B | TA/B | A/B | |
Dasatinib | A/Q | A/Q | Q | A | Â | Q | Q | Â | Â | A | Â | A | Â | Â | Q | A/Q | Q | A/Q | TA/Q* | TA* | TA* | A | |
Erlotinib | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | T/D | T* | T* | T D | Â | |
Gefitinib | T | Â | Â | Â | Â | Â | Â | A | Â | Â | Â | Â | Â | Â | Â | Â | Â | T | T | T | T | Â | |
Ibrutinib | A | Â | Â | Â | Â | Â | Â | Â | Â | A | Â | Â | A | Â | Â | Â | Â | TA | T/D | TA/D | TA* | A | |
Imatinib | TA | A | Â | A | Â | Â | A | A | Â | TA | Â | TA | A | Â | Â | A | Â | TA | TA | TA | TA | A | |
Lapatinib | TA/Q | Q | Q | Â | Â | Q | Q | Â | Â | TA | Â | T | A | Â | Q | A/Q | Q | TA/Q | T/Q* | TA* | TA* | A | |
Lenvatinib | Q | Q | Q | Â | Â | Q | Q | Â | Â | T | Â | T | Â | Â | Q | Q | Q | Q | Q | T | T | Â | |
Nilotinib | Q | Q | Q | A | A | Q | Q | A | Â | TA | Â | TA | A | A | Q | Q | Q | Q | Q* | TA* | TA* | A | |
Osimertinib | Q | Q | Q | A | A | A/Q | A/Q | Â | Â | TA | Â | TA | Â | Â | Q | Q | Q | Q | Q | TA | TA | A | |
Pazopanib | T/Q | Q | Q | Â | Â | Q | Q | A | Â | T | Â | T | Â | Â | Q | Q | Q | T/Q | T/Q* | T* | T* | Â | |
Ponatinib | T/A | Â | Â | Â | Â | Â | Â | Â | Â | TA | Â | T | A | Â | Â | Â | Â | TA | T* | TA* | TA* | A | |
Regorafenib | A | Â | Â | Â | Â | Â | Â | B | B | A/B | B | B | A/B | B | B | Â | Â | A/B | T/B | TA/B | TA/B | A/B | |
Ruxolitinib | Â | Â | Â | Â | Â | Â | B | B | B | B | B | B | B | B | B | Â | Â | B | T/B* | T/B* | T/B* | B | |
Sorafenib | A/Q | Q | Q | A | Â | Q | Q | Â | Â | A | Â | Â | Â | Â | Q | Q | Q | Q | T/Q | TA | TA | Â | |
Sunitinib | A/Q | Q | Q | Â | Â | Q | Q | Â | Â | A | Â | Â | A | Â | Q | Q | Q | A/Q | T/Q* | TA* | TA* | A | |
Vandetanib | Q | Q | Q | Â | Â | Q | Q | Â | Â | A | Â | Â | A | Â | Q | Q | Q | Q | Q | TA | TA | A | |
- Drug-drug interactions are predicted based on pharmacokinetics, given the limited data available from patient studies
- Underlined = "Alter combination" Bold = "Combination is contraindicated"
-
